Antibody data
- Antibody Data
- Antigen structure
- References [4]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 26620-1-AP - Provider product page

- Provider
- Proteintech Group
- Product name
- RHOV antibody
- Antibody type
- Polyclonal
- Description
- RHOV antibody (Cat. #26620-1-AP) is a rabbit polyclonal antibody that shows reactivity with human, rat and has been validated for the following applications: IHC, WB,ELISA.
- Reactivity
- Human, Rat
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 20ul, 150ul
Submitted references RHOV is a Detachment-Responsive Rho GTPase Necessary for Ovarian Cancer Peritoneal Metastasis.
RHOV is a Detachment-Responsive Rho GTPase Necessary for Ovarian Cancer Peritoneal Metastasis.
RHOV promotes lung adenocarcinoma cell growth and metastasis through JNK/c-Jun pathway.
Overexpression of RhoV Promotes the Progression and EGFR-TKI Resistance of Lung Adenocarcinoma.
Elhaw AT, Tang PW, Cheng YY, Kamlapurkar S, Javed Z, Al-Saad S, White SR, Abdelnaby AE, Khan H, Choi AS, Mattheyses AL, Cole AR, Kim YS, Atiya HI, Trebak M, Zervantonakis IK, Buckanovich RJ, Aird KM, Coffman LG, Mythreye K, Hempel N
Cancer research 2026 Apr 16;
Cancer research 2026 Apr 16;
RHOV is a Detachment-Responsive Rho GTPase Necessary for Ovarian Cancer Peritoneal Metastasis.
Elhaw AT, Tang PW, Cheng YY, Kamlapurkar S, Javed Z, Al-Saad S, White SR, Abdelnaby AE, Khan H, Choi AS, Cole AR, Kim YS, Atiya HI, Trebak M, Zervantonakis I, Buckanovich RJ, Aird KM, Coffman LG, Mythreye K, Hempel N
bioRxiv : the preprint server for biology 2025 Aug 13;
bioRxiv : the preprint server for biology 2025 Aug 13;
RHOV promotes lung adenocarcinoma cell growth and metastasis through JNK/c-Jun pathway.
Zhang D, Jiang Q, Ge X, Shi Y, Ye T, Mi Y, Xie T, Li Q, Ye Q
International journal of biological sciences 2021;17(10):2622-2632
International journal of biological sciences 2021;17(10):2622-2632
Overexpression of RhoV Promotes the Progression and EGFR-TKI Resistance of Lung Adenocarcinoma.
Chen H, Xia R, Jiang L, Zhou Y, Xu H, Peng W, Yao C, Zhou G, Zhang Y, Xia H, Wang Y
Frontiers in oncology 2021;11:619013
Frontiers in oncology 2021;11:619013
No comments: Submit comment
No validations: Submit validation data